bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
Authors: Yeung Jacky T. , Hamilton Ronald L. , Ohnishi Koji , Ikeura Maki , Potter Douglas M. , Nikiforova Marina N. , Ferrone Soldano , Jakacki Regina I. , Pollack Ian F. , Okada Hideho
Published: April 2023

PDF file - 67K, Characteristics of patients who underwent standard of care.
Supplementary Figure 2 from Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent
Authors: Pinto Emilia M. , Morton Christopher , Rodriguez-Galindo Carlos , McGregor Lisa , Davidoff Andrew M. , Mercer Kimberly , Debelenko Larisa V. , Billups Catherine , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

PDF file - 73K, Expression of p53 and IGF2 in normal adrenal cortex and xenograft tumor
Supplementary Figure 1 from Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent
Authors: Pinto Emilia M. , Morton Christopher , Rodriguez-Galindo Carlos , McGregor Lisa , Davidoff Andrew M. , Mercer Kimberly , Debelenko Larisa V. , Billups Catherine , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

PDF file - 285K, Identification of TP53-G245C mutation in the germline, primary ACC and xenograft tumor
Supplementary Figure Legend from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Authors: Mulligan Anna Marie , Raitman Irene , Feeley Linda , Pinnaduwage Dushanthi , Nguyen Linh T. , O'Malley Frances P. , Ohashi Pamela S. , Andrulis Irene L.
Published: April 2023

PDF file - 56K
Supplementary Figure 2 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Authors: Mulligan Anna Marie , Raitman Irene , Feeley Linda , Pinnaduwage Dushanthi , Nguyen Linh T. , O'Malley Frances P. , Ohashi Pamela S. , Andrulis Irene L.
Published: April 2023

PDF file - 10654K, Supplementary Figure S2: (A) Representative CD4 stained TMA (x1.25). (B) Invasive carcinoma showing absence of intratumoral CD4+ lymphocytes (x20). (C-D) Intratumoral CD4+ lymphocytes (x20, x40, respectively). (E-F) Peritumoral CD4+ lymphocytes (x20, x40, respectively). (G) Representative CD8 stained TMA (x1.25). (H) Invasive carcinoma showing absence of intratumoral CD8+ lymphocytes (x20). (I-J) Rare CD8+ intratumoral lymphocytes (<10) (x20, x40, respectively). (K-L) Intratumoral CD8+ lymphocytes (>10) (x20, x40, respectively). (M-N) Predominantly peritumoral CD8+ lymphocytes (>10) (x20, x40, respectively).
Supplementary Figure Legends from Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Authors: Cheng Zhixiang , Gong Yuanying , Ma Yufang , Lu Kaihua , Lu Xiang , Pierce Larry A. , Thompson Reid C. , Muller Susanne , Knapp Stefan , Wang Jialiang
Published: April 2023

PDF file - 26 KB
Supplementary Figure 2 from In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
Authors: Fonte Eleonora , Apollonio Benedetta , Scarfò Lydia , Ranghetti Pamela , Fazi Claudia , Ghia Paolo , Caligaris-Cappio Federico , Muzio Marta
Published: April 2023

PDF file - 1992K, Relative viability of CLL cells
Supplementary Figure 1 from MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation
Authors: Wermke Martin , Schmidt Anne , Middeke Jan Moritz , Sockel Katja , von Bonin Malte , Schönefeldt Claudia , Mair Sabine , Plodeck Verena , Laniado Michael , Weiss Günter , Schetelig Johannes , Ehninger Gerhard , Theurl Igor , Bornhäuser Martin , Platzbecker Uwe
Published: April 2023

PDF file - 98K, Graph depicting sensitivity, specificity and accuracy of different LIC thresholds for the prediction of Overall Survival
supplemental legend from Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy
Authors: Lu Yen-Shen , Chen Tom Wei-Wu , Lin Ching-Hung , Yeh Dah-Cherng , Tseng Ling-Ming , Wu Pei-Fang , Rau Kun-Ming , Chen Bang-Bin , Chao Ta-Chung , Huang Shu-Min , Huang Chiun-Sheng , Shih Tiffany Ting-Fang , Cheng Ann-Lii
Published: April 2023

supplemental legend
Supplementary Table 1, Figures 1 - 3 from Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma
Authors: Li Zhijie , Yan Shuang , Attayan Navid , Ramalingam Sridevi , Thiele Carol J.
Published: April 2023

PDF file, 157KB, Table S1. Specific mutations in neuroblastoma (NB) cell lines Fig. S1: The combination of MK-2206 and cisplatin induced a synergistic effect on the inhibition of cell proliferation in NB cells. Fig. S2: ROS inhibitor α-Tocopherol blocked the synergistic effect of MK-2206 and rapamycin on cell proliferation. Fig. S3: A combination of MK-2206 and rapamycin induced a higher ROS production compared to MK-2206 alone.
Supplementary Table 1 from Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
Authors: Kalota Anna , Jeschke Grace R. , Carroll Martin , Hexner Elizabeth O.
Published: April 2023

PDF file - 21K, pSTAT5 in CD15+ cells treated with CEP701 (20 μM): myelofibrosis is significantly more resistant to JAK2 inhibition than PV, ET and normal
Figure S1 from Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Kannan Anbarasu , Wells Robert B. , Sivakumar Subramaniam , Komatsu Satoshi , Singh Karan P. , Samten Buka , Philley Julie V. , Sauter Edward R. , Ikebe Mitsuo , Idell Steven , Gupta Sudeep , Dasgupta Santanu
Published: April 2023

Influence of SH3GL2 overexpression in BCa cells.
Supplementary Figure 2 from Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients
Authors: Mayerhoefer Marius E. , Karanikas Georgios , Kletter Kurt , Prosch Helmut , Kiesewetter Barbara , Skrabs Cathrin , Porpaczy Edit , Weber Michael , Pinker-Domenig Katja , Berzaczy Dominik , Hoffmann Martha , Sillaber Christian , Jaeger Ulrich , Müllauer Leonhard , Simonitsch-Klupp Ingrid , Dolak Werner , Gaiger Alexander , Ubl Philipp , Lukas Julius , Raderer Markus
Published: April 2023

PDF file - 455KB, A 56-year old male patient with histologically verified, infra-diaphragmatic SLL/CLL in the retroperitoneal/paraaortic lymph nodes (light blue arrows). These nodal lymphoma manifestations show a high signal (i.e., diffusion restriction) on DWI and the fused color-coded DWI-MRI images, and were thus rated as positive. On the other hand, they fail to show an elevated tracer uptake, relative to the surrounding tissues, on the 18F-FDG-PET and the fused color-coded PET/CT images, and were thus rated as negative. On CE-CT, the lymph nodes were rated as positive due to their abnormal long-axis diameter (>1.5 cm).
Supplementary figure 4 from OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
Authors: Lai Chester , August Suzannah , Albibas Amel , Behar Ramnik , Cho Shin-Young , Polak Marta E. , Theaker Jeffrey , MacLeod Amanda S. , French Ruth R. , Glennie Martin J. , Al-Shamkhani Aymen , Healy Eugene
Published: April 2023

Supplementary figure 4: cSCC blood vessels express e-selectin.
Supplementary figure 2 from OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential
Authors: Lai Chester , August Suzannah , Albibas Amel , Behar Ramnik , Cho Shin-Young , Polak Marta E. , Theaker Jeffrey , MacLeod Amanda S. , French Ruth R. , Glennie Martin J. , Al-Shamkhani Aymen , Healy Eugene
Published: April 2023

Supplementary figure 2: CLA is expressed by tumoral T cells and Tregs in cSCCs.
Supplementary Figures 1 - 2 from p53 Arg72Pro Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-Analysis
Authors: Habbous Steven , Pang Vincent , Eng Lawson , Xu Wei , Kurtz Goldie , Liu Fei-Fei , Mackay Helen , Amir Eitan , Liu Geoffrey
Published: April 2023

PDF file - 108K, Supplementary Figure 1. Funnel plot for included studies that evaluated overall risk. The included studies were summarized in Supplementary Table 1. Supplementary Figure 2. Forest plot with OR for risk of cervical cancer compared to normal controls. OR and heterogeneity measures are shown for each subset as a subtotal A) HPV positive subset; B) HPV negative subset and for the pooled analysis as a total. Weights of individual studies are represented by black boxes. Diamonds represent weighted OR with 95% confidence limits. Recessive model shown.
Supplementary Information from A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
Authors: Goff Laura W. , Cohen Roger B. , Berlin Jordan D. , de Braud Filippo G. , Lyshchik Andrej , Noberasco Cristina , Bertolini Francesco , Carpentieri Marina , Stampino Corrado Gallo , Abbattista Antonello , Wang Erjan , Borghaei Hossein
Published: April 2023

Additional Methods; Tables and Figure [1]Supplementary Methods: Contrast-enhanced ultrasound (CE-US) [2]Supplementary Table S1. Pharmacokinetic characteristics of PF-03446962 following single-dose administration in cycle 1 [3]Supplementary Table S2. Best overall tumor response in patients treated with PF-03446962 [4]Supplementary Figure S1. Telangiectasia observed in patients treated with PF-03446962.
Supplementary Table S6 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Authors: Braggio Esteban , Van Wier Scott , Ojha Juhi , McPhail Ellen , Asmann Yan W. , Egan Jan , da Silva Jackline Ayres , Schiff David , Lopes M. Beatriz , Decker Paul A. , Valdez Riccardo , Tibes Raoul , Eckloff Bruce , Witzig Thomas E. , Stewart A. Keith , Fonseca Rafael , O'Neill Brian Patrick
Published: April 2023

Supplementary Table S6. Metrics in all samples analyzed by WES. FFPE: formalin-fixed paraffin-embedded.
Supplementary Table S4 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Authors: Braggio Esteban , Van Wier Scott , Ojha Juhi , McPhail Ellen , Asmann Yan W. , Egan Jan , da Silva Jackline Ayres , Schiff David , Lopes M. Beatriz , Decker Paul A. , Valdez Riccardo , Tibes Raoul , Eckloff Bruce , Witzig Thomas E. , Stewart A. Keith , Fonseca Rafael , O'Neill Brian Patrick
Published: April 2023

Supplementary Table S4. FISH analysis performed in PCNSL cases. WT: wild type; 1N: monoallelic deletion; 0N: biallelic deletion.
Supplemental Figure 3 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Authors: Bacac Marina , Fauti Tanja , Sam Johannes , Colombetti Sara , Weinzierl Tina , Ouaret Djamila , Bodmer Walter , Lehmann Steffi , Hofer Thomas , Hosse Ralf J. , Moessner Ekkehard , Ast Oliver , Bruenker Peter , Grau-Richards Sandra , Schaller Teilo , Seidl Annette , Gerdes Christian , Perro Mario , Nicolini Valeria , Steinhoff Nathalie , Dudal Sherri , Neumann Sebastian , von Hirschheydt Thomas , Jaeger Christiane , Saro Jose , Karanikas Vaios , Klein Christian , Umaña Pablo
Published: April 2023

Detection of tumor targeting by in vivo imaging (fluorescent intensity, FLI)of CEA TCB formats having bivalent or monovalent binding to CEA and directly labeled with Alexa647.
Supplemental Figure 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Authors: Bacac Marina , Fauti Tanja , Sam Johannes , Colombetti Sara , Weinzierl Tina , Ouaret Djamila , Bodmer Walter , Lehmann Steffi , Hofer Thomas , Hosse Ralf J. , Moessner Ekkehard , Ast Oliver , Bruenker Peter , Grau-Richards Sandra , Schaller Teilo , Seidl Annette , Gerdes Christian , Perro Mario , Nicolini Valeria , Steinhoff Nathalie , Dudal Sherri , Neumann Sebastian , von Hirschheydt Thomas , Jaeger Christiane , Saro Jose , Karanikas Vaios , Klein Christian , Umaña Pablo
Published: April 2023

Pharmacokinetic profiles of CEA TCB in mice, additional information on CD3 signaling, T cell activation, tumor cell lysis and cytokine release upon CEA TCB and untargeted control TCB treatment.
Supplemental Table 4 from Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Authors: Zhong Yi , Macgregor-Das Anne , Saunders Tyler , Whittle Martin C. , Makohon-Moore Alvin , Kohutek Zachary A. , Poling Justin , Herbst Brian T. , Javier Breanna M. , Cope Leslie , Leach Steven D. , Hingorani Sunil R. , Iacobuzio-Donahue Christine A.
Published: April 2023

Gene Ontology Analysis of KPC and KPTC Secretome
Supplemental Figure 3 from Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer
Authors: Zhong Yi , Macgregor-Das Anne , Saunders Tyler , Whittle Martin C. , Makohon-Moore Alvin , Kohutek Zachary A. , Poling Justin , Herbst Brian T. , Javier Breanna M. , Cope Leslie , Leach Steven D. , Hingorani Sunil R. , Iacobuzio-Donahue Christine A.
Published: April 2023

Histologic features of liver metastases in KPTC, KPC, KTC and KC mice.
Supplementary Figures legend from APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells
Authors: Cagnetta Antonia , Caffa Irene , Acharya Chirag , Soncini Debora , Acharya Prakrati , Adamia Sophia , Pierri Ivana , Bergamaschi Micaela , Garuti Anna , Fraternali Giulio , Mastracci Luca , Provenzani Alessandro , Zucal Chiara , Damonte Gianluca , Salis Annalisa , Montecucco Fabrizio , Patrone Franco , Ballestrero Alberto , Bruzzone Santina , Gobbi Marco , Nencioni Alessio , Cea Michele
Published: April 2023

Supplementary Figures legend
Supplemental Figure S2 from Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells
Authors: Nguyen Le Xuan Truong , Zhu Li , Lee Yunqin , Ta Lynn , Mitchell Beverly S.
Published: April 2023

Supplemental Figure S2. Effects of Ebp1 depletion on cell proliferation in K562 leukemic cells.
Supplementary Table 6 from Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival
Authors: Yap Kai Lee , Kiyotani Kazuma , Tamura Kenji , Antic Tatjana , Jang Miran , Montoya Magdeline , Campanile Alexa , Yew Poh Yin , Ganshert Cory , Fujioka Tomoaki , Steinberg Gary D. , O'Donnell Peter H. , Nakamura Yusuke
Published: April 2023

Frequencies of mutations in genes previously reported6-8,10 as observed in our panel of bladder carcinoma patients.
Table S4 from Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
Authors: Katsila Theodora , Juliachs Mercè , Gregori Josep , Macarulla Teresa , Villarreal Laura , Bardelli Alberto , Torrance Chris , Elez Elena , Tabernero Josep , Villanueva Josep
Published: April 2023

Gene ontology description of the 301 G12V unique proteins shown in Figure 2B
Supplemental Figure 1 from First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Authors: Starodub Alexander N. , Ocean Allyson J. , Shah Manish A. , Guarino Michael J. , Picozzi Vincent J. , Vahdat Linda T. , Thomas Sajeve S. , Govindan Serengulam V. , Maliakal Pius P. , Wegener William A. , Hamburger Steven A. , Sharkey Robert M. , Goldenberg David M.
Published: April 2023

Trop-2 expression in archived tissue specimens from 6 patients enrolled in the clinical trial with sacituzumab govitecan.
Supplementary Table 3 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Authors: Li Xinqun , Truty Mark A. , Kang Ya'an , Chopin-Laly Xavier , Zhang Ran , Roife David , Chatterjee Deyali , Lin E. , Thomas Ryan M. , Wang Huamin , Katz Matthew H. , Fleming Jason B.
Published: April 2023

Multivariate Analysis of Factors Associated with Overall Survival, Recurrence-Free Survival, and Liver-Specific Recurrence-Free Survival.
Figure S3 from Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Georgen Maria R. , Aburjania Zviadi , Somnay Yash R. , Leverson Glen , Sippel Rebecca S. , Lloyd Ricardo V. , Johnson Brian P. , Chen Herbert
Published: April 2023

RFP-positive FTC236-Notch1 cells for the establishment of orthotopic mouse model. (A). Over 26% of the cells from the initial transduced batch were positive for RFP and were sorted for further culturing. (B). The sorted cells were cultured for 3 passages and over 96% were RFP-positive. (C). The sorted cells were cultured for 6 passages and 97% were RFP-positive.
Supplementary Figure 2 from Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Authors: Sanmamed Miguel F. , Carranza-Rua Omar , Alfaro Carlos , Oñate Carmen , Martín-Algarra Salvador , Perez Guiomar , Landazuri Sara F. , Gonzalez Álvaro , Gross Stefanie , Rodriguez Inmaculada , Muñoz-Calleja Cecilia , Rodríguez-Ruiz María , Sangro Bruno , López-Picazo José M. , Rizzo Manglio , Mazzolini Guillermo , Pascual Juan I. , Andueza Maria Pilar , Perez-Gracia Jose Luis , Melero Ignacio
Published: April 2023

Supplementary Figure 2. Serum IL-8 levels before (day -1) and after (day 5-7) disease-reduction surgery of 7 patients: 1 hepatocellular carcinoma (HCC); 2 colorectal carcinoma (CRC); 1 pancreatic cancer (PC); 3 renal cell carcinoma (RCC).
Supplemental Table 1 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

Contains a list of genes regulated by FGFR3 shRNA in RT112 cells.
Supplemental Figure 5 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

R3Mab attenuates xenograft growth of UMUC-14 tumors.
Supplementary Table 1 - 7 from Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Authors: Mack Stephen C. , Agnihotri Sameer , Bertrand Kelsey C. , Wang Xin , Shih David J. , Witt Hendrik , Hill Nadia , Zayne Kory , Barszczyk Mark , Ramaswamy Vijay , Remke Marc , Thompson Yuan , Ryzhova Marina , Massimi Luca , Grajkowska Wieslawa , Lach Boleslaw , Gupta Nalin , Weiss William A. , Guha Abhijit , Hawkins Cynthia , Croul Sidney , Rutka James T. , Pfister Stefan M. , Korshunov Andrey , Pekmezci Melike , Tihan Tarik , Philips Joanna J. , Jabado Nada , Zadeh Gelareh , Taylor Michael D.
Published: April 2023

Supplementary Table 1 - 7. Supplementary Table 1: Clinical and histopathological data associated with all spinal ependymomas analyzed in this study, along with molecular subgroup assignment; Supplementary Table 2: Table of all antibodies used in this study, their commercial sources, and dilutions used; Supplementary Table 3: Table of differentially expressed genes between spinal grade II and myxopapillary ependymoma; Supplementary Table 4: Summary of focal amplifications detected in spinal ependymoma by GISTIC2; Supplementary Table 5: Summary of focal deletions detected in spinal ependymoma by GISTIC2; Supplementary Table 6: List of significant pathways enriched by Gene Set Enrichment Analysis in spinal grade II ependymoma; Supplementary Table 7: List of significant pathways enriched by Gene Set Enrichment Analysis in spinal myxopapillary ependymoma
Supplementary Figure 6 from Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Authors: Mack Stephen C. , Agnihotri Sameer , Bertrand Kelsey C. , Wang Xin , Shih David J. , Witt Hendrik , Hill Nadia , Zayne Kory , Barszczyk Mark , Ramaswamy Vijay , Remke Marc , Thompson Yuan , Ryzhova Marina , Massimi Luca , Grajkowska Wieslawa , Lach Boleslaw , Gupta Nalin , Weiss William A. , Guha Abhijit , Hawkins Cynthia , Croul Sidney , Rutka James T. , Pfister Stefan M. , Korshunov Andrey , Pekmezci Melike , Tihan Tarik , Philips Joanna J. , Jabado Nada , Zadeh Gelareh , Taylor Michael D.
Published: April 2023

Supplementary Figure 6. A schematic of the glycolytic pathway in myxopapillary ependymoma illustrating deregulation of proteins and metabolites and possible targets for therapeutic intervention.
Supplementary Figure 2 from Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Authors: Mack Stephen C. , Agnihotri Sameer , Bertrand Kelsey C. , Wang Xin , Shih David J. , Witt Hendrik , Hill Nadia , Zayne Kory , Barszczyk Mark , Ramaswamy Vijay , Remke Marc , Thompson Yuan , Ryzhova Marina , Massimi Luca , Grajkowska Wieslawa , Lach Boleslaw , Gupta Nalin , Weiss William A. , Guha Abhijit , Hawkins Cynthia , Croul Sidney , Rutka James T. , Pfister Stefan M. , Korshunov Andrey , Pekmezci Melike , Tihan Tarik , Philips Joanna J. , Jabado Nada , Zadeh Gelareh , Taylor Michael D.
Published: April 2023

Supplementary Figure 2. Summary of focal copy number alterations detected by GISTIC2 in spinal Grade II and Myxopapillary Ependymoma.
Supplemental Figure 3 from Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers
Authors: Boufraqech Myriem , Zhang Lisa , Nilubol Naris , Sadowski Samira M. , Kotian Shweta , Quezado Martha , Kebebew Electron
Published: April 2023

TIMP4 expression in cancer cells
Movie S3 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Authors: Luo Haiming , England Christopher G. , Shi Sixiang , Graves Stephen A. , Hernandez Reinier , Liu Bai , Theuer Charles P. , Wong Hing C. , Nickles Robert J. , Cai Weibo
Published: April 2023

Movie S3 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Supplementary Figure S9 from Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Song Ahnah , Kim Tae Min , Kim Dong-Wan , Kim Soyeon , Keam Bhumsuk , Lee Se-Hoon , Heo Dae Seog
Published: April 2023

Supplementary Figure S9: Relative expression levels of p-EGFR (Tyr1068) and total EGFR in HCC78 and HCC78CR3 cells treated with vehicle or crizotinib.
Supplemental Figure 4 from Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Authors: Veldman-Jones Margaret H. , Lai Zhongwu , Wappett Mark , Harbron Chris G. , Barrett J. Carl , Harrington Elizabeth A. , Thress Kenneth S.
Published: April 2023

Supplemental Figure 4. Comparison of NanoString codeset with Scott et al
Supplementary Figure S4. from Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2
Authors: Geller David S. , Singh Michael Y. , Zhang Wendong , Gill Jonathan , Roth Michael E. , Kim Mimi Y. , Xie Xianhong , Singh Christopher K. , Dorfman Howard D. , Villanueva-Siles Esperanza , Park Amy , Piperdi Sajida , Gorlick Richard
Published: April 2023

Supplementary Figure S4. ROC curves for OS187 recurrence vs. average soft-tissue margin length.
Supplementary Figure S3. from Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2
Authors: Geller David S. , Singh Michael Y. , Zhang Wendong , Gill Jonathan , Roth Michael E. , Kim Mimi Y. , Xie Xianhong , Singh Christopher K. , Dorfman Howard D. , Villanueva-Siles Esperanza , Park Amy , Piperdi Sajida , Gorlick Richard
Published: April 2023

Supplementary Figure S3. ROC curves for OS187 recurrence vs. average bone margin length.
Supplemental Figure 3 from High Levels of Antibody that Neutralize B-cell Infection of Epstein–Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma
Authors: Coghill Anna E. , Bu Wei , Nguyen Hanh , Hsu Wan-Lun , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Chen Chien-Jen , Hildesheim Allan , Cohen Jeffrey I.
Published: April 2023

Correlation of anti-gH/gL antibodies with B-cell infection neutralization.
Supplementary Figure 2 from A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
Authors: Pardee Timothy S. , Lee King , Luddy John , Maturo Claudia , Rodriguez Robert , Isom Scott , Miller Lance D. , Stadelman Kristin M. , Levitan Denise , Hurd David , Ellis Leslie R. , Harrelson Robin , Manuel Megan , Dralle Sarah , Lyerly Susan , Powell Bayard L.
Published: April 2023

Supplementary Figure 2. Differential gene expression between responders and non-responders. The top 50 genes up regulated in responders (left side) or non-responders (right side) in PBMCs from 4 responders compared to 4 non-responders taken on day 1 of week 4. Red color indicates above-mean expression, green color indicates below-mean expression. Degree of color saturation reflects the magnitude of change. R= responders, N= non-responders. FC= the mean log base 2 fold change.
Figure S1 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Authors: Giraldo Nicolas A. , Becht Etienne , Pagès Franck , Skliris Georgios , Verkarre Virginie , Vano Yann , Mejean Arnaud , Saint-Aubert Nicolas , Lacroix Laetitia , Natario Ivo , Lupo Audrey , Alifano Marco , Damotte Diane , Cazes Aurelie , Triebel Frederic , Freeman Gordon J. , Dieu-Nosjean Marie-Caroline , Oudard Stephane , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Figure S1. Test of the specificity of anti-immune checkpoints : Immunohistochemical staining of immune checkpoints on sections from paraffin embedded cell pellets of untransfected and transfected cell lines used as negative and positive controls respectively and from paraffin embedded tonsils and placenta.
Supplementary Table 1 Overall Mortality_legend from Association between GWAS-Derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer
Authors: Świerniak Michał , Wójcicka Anna , Czetwertyńska Małgorzata , Długosińska Joanna , Stachlewska Elżbieta , Gierlikowski Wojciech , Kot Adam , Górnicka Barbara , Koperski Łukasz , Bogdańska Magdalena , Wiechno Wiesław , Jażdżewski Krystian
Published: April 2023

Supplementary Table 1 Overall Mortality_legend
Supplementary Figures 1-4 from Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions
Authors: Damelin Marc , Bankovich Alexander , Park Albert , Aguilar Jorge , Anderson Wade , Santaguida Marianne , Aujay Monette , Fong Sarah , Khandke Kiran , Pulito Virginia , Ernstoff Elana , Escarpe Paul , Bernstein Jeffrey , Pysz Marybeth , Zhong Wenyan , Upeslacis Erik , Lucas Judy , Lucas Justin , Nichols Timothy , Loving Kathryn , Foord Orit , Hampl Johannes , Stull Robert , Barletta Frank , Falahatpisheh Hadi , Sapra Puja , Gerber Hans-Peter , Dylla Scott J.
Published: April 2023

Supplementary Figures 1-4. Supplementary Figure 1. Analysis of EFNA4 copy number in breast and hepatocellular carcinoma. Supplementary Figure 2. Characterization of PF-06647263 conjugates. Supplementary Figure 3. Biomarkers of PF-06647263 activity in breast PDX tumors. Supplementary Figure 4. Characterization of EFNA4 affinity for EphA and EphB receptors.
Table S1 from PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Authors: Madore Jason , Strbenac Dario , Vilain Ricardo , Menzies Alexander M. , Yang Jeen Y. H. , Thompson John F. , Long Georgina V. , Mann Graham J. , Scolyer Richard A. , Wilmott James S.
Published: April 2023

Table S1 - Summary of Gene Set Enrichment Analysis (GSEA) results for pathways with FDR < 0.05.
Supplementary Figure Legends from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Authors: Nakaoku Takashi , Tsuta Koji , Ichikawa Hitoshi , Shiraishi Kouya , Sakamoto Hiromi , Enari Masato , Furuta Koh , Shimada Yoko , Ogiwara Hideaki , Watanabe Shun-ichi , Nokihara Hiroshi , Yasuda Kazuki , Hiramoto Masaki , Nammo Takao , Ishigame Teruhide , Schetter Aaron J. , Okayama Hirokazu , Harris Curtis C. , Kim Young Hak , Mishima Michiaki , Yokota Jun , Yoshida Teruhiko , Kohno Takashi
Published: April 2023

PDF file - 115KB
Supplementary Table S2 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Authors: Taube Janis M. , Young Geoffrey D. , McMiller Tracee L. , Chen Shuming , Salas January T. , Pritchard Theresa S. , Xu Haiying , Meeker Alan K. , Fan Jinshui , Cheadle Chris , Berger Alan E. , Pardoll Drew M. , Topalian Suzanne L.
Published: April 2023

Supplementary Table S2: 1660 Illumina probes up-regulated at least 2-fold in PD-L1+ melanomas
Supplementary Table S1, Supplementary Table S3, Supplementary Table S5 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Authors: Taube Janis M. , Young Geoffrey D. , McMiller Tracee L. , Chen Shuming , Salas January T. , Pritchard Theresa S. , Xu Haiying , Meeker Alan K. , Fan Jinshui , Cheadle Chris , Berger Alan E. , Pardoll Drew M. , Topalian Suzanne L.
Published: April 2023

Supplementary Table S1, Supplementary Table S3, Supplementary Table S5. Supplementary Table S1: Genes selected for multiplex qRT-PCR array Supplementary Table S3: Functionally annotated gene categories from DAVID analysis of whole genome microarray results comparing PD-L1+ to PD-L1(-) melanomas. Supplementary Table S5: Genes over-expressed in PD-L1+ vs. PD-L1(-) melanomas, assessed by qRT-PCR.
Supplemental Figures 1-4 from A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
Authors: Smith David C. , Eisenberg Peter D. , Manikhas Georgy , Chugh Rashmi , Gubens Matthew A. , Stagg Robert J. , Kapoun Ann M. , Xu Lu , Dupont Jakob , Sikic Branimir
Published: April 2023

Supplemental Figures 1-4. Supplemental Figure 1: Group Mean Concentration-Time Profiles and the Linear 2 Compartment Model Fit For Weekly Dosing Cohorts Supplemental Figure 2: Effect of Demcizumab on Hair Follicle Biomarkers Supplemental Figure 3: Effect of Demcizumab on Plasma Proteins Supplemental Figure 4: Duration on Study by Patient
Supplementary Table 5 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Authors: Azad Arun A. , Volik Stanislav V. , Wyatt Alexander W. , Haegert Anne , Le Bihan Stephane , Bell Robert H. , Anderson Shawn A. , McConeghy Brian , Shukin Robert , Bazov Jenny , Youngren Jack , Paris Pamela , Thomas George , Small Eric J. , Wang Yuzhuo , Gleave Martin E. , Collins Colin C. , Chi Kim N.
Published: April 2023

Supplementary Table 5. Univariate and multivariate analysis examining association between pre-treatment clinico-pathological factors and progression-free survival (radiographic and/or clinical) in patients switched onto enzalutamide after collection of circulating cell-free DNA (n = 39)
Supplementary Table 4 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Authors: Azad Arun A. , Volik Stanislav V. , Wyatt Alexander W. , Haegert Anne , Le Bihan Stephane , Bell Robert H. , Anderson Shawn A. , McConeghy Brian , Shukin Robert , Bazov Jenny , Youngren Jack , Paris Pamela , Thomas George , Small Eric J. , Wang Yuzhuo , Gleave Martin E. , Collins Colin C. , Chi Kim N.
Published: April 2023

Supplementary Table 4. Univariate analysis examining association between baseline clinico-pathological factors and PSA response in patients switched onto enzalutamide after collection of circulating cell-free DNA (n = 39)
Supplemental Table 1 from Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma
Authors: Satoh Kei , Zhang Lisa , Zhang Yaqin , Chelluri Raju , Boufraqech Myriem , Nilubol Naris , Patel Dhaval , Shen Min , Kebebew Electron
Published: April 2023

Supplemental Table 1 shows compounds that are pan-active in all three adrenocortical carcinoma cell lines (NCI-H295R, BD140A and SW-13).
Supplementary Figure 1 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Authors: Azad Arun A. , Volik Stanislav V. , Wyatt Alexander W. , Haegert Anne , Le Bihan Stephane , Bell Robert H. , Anderson Shawn A. , McConeghy Brian , Shukin Robert , Bazov Jenny , Youngren Jack , Paris Pamela , Thomas George , Small Eric J. , Wang Yuzhuo , Gleave Martin E. , Collins Colin C. , Chi Kim N.
Published: April 2023

Supplementary Figure 1. Comparison of AR, MYC, CCND1 and CCNE1 copy number status in 5 patients with matched circulating cell-free DNA and tumor biopsies subjected to array comparative genomic hybridization
Supp Data from Tumor Evolution Inferred by Patterns of microRNA Expression through the Course of Disease, Therapy, and Recurrence in Breast Cancer
Authors: Dadiani Maya , Bossel Ben-Moshe Noa , Paluch-Shimon Shani , Perry Gili , Balint Nora , Marin Irina , Pavlovski Anya , Morzaev Dana , Kahana-Edwin Smadar , Yosepovich Ady , Gal-Yam Einav Nili , Berger Raanan , Barshack Iris , Domany Eytan , Kaufman Bella
Published: April 2023

Supplementary methods Figure S1: The types of samples that were collected for each patient from cohort 2 (recurrence-freee patients). Figure S2: qPCR validations for Nanostring expression measurements. Figure S3: P1 miRNAs expression levels pre- and post-treatment versus normal breast tissue. Figure S4: miR-10b* expression levels. Figure S5: P1 miRNAs and their cell cycle predicted targets BUB1B and CDC25A. Figure S6: P1 scores and Ki67 levels by immunostaining. Figure S7: P1 scores in the METABRIC dataset. Figure S8: P2 miRNAs differentiate between recurrence and recurrence-free patients. Figure S9: P1 and P2 expression levels in ER-positive patients alone. Figure S10: Enrichment of EMT-induced genes in the correlated genes to P5 miRNAs. Figure S11: P5 and P6 miRNAs expression levels at post-treatment lymph nodes approach the levels at recurrence. Figure S12: Effects of the thresholds on the number of miRNAs that were classified to a pattern. Table S1: Miller and Payne grades and RCB classes Table S2: miRNAs' potential role in breast cancer from the literature Table S3: Pathway analysis; shared correlatred pathways across each pattern Table S4: Target genes for P1 miRNAs
Supplementary Figure S5 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Authors: Brown Christine E. , Badie Behnam , Barish Michael E. , Weng Lihong , Ostberg Julie R. , Chang Wen-Chung , Naranjo Araceli , Starr Renate , Wagner Jamie , Wright Christine , Zhai Yubo , Bading James R. , Ressler Julie A. , Portnow Jana , D'Apuzzo Massimo , Forman Stephen J. , Jensen Michael C.
Published: April 2023

Supplementary Figure S5. T cell detection in tumor tissue from UPN031.
Supplementary Figure S4 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Authors: Brown Christine E. , Badie Behnam , Barish Michael E. , Weng Lihong , Ostberg Julie R. , Chang Wen-Chung , Naranjo Araceli , Starr Renate , Wagner Jamie , Wright Christine , Zhai Yubo , Bading James R. , Ressler Julie A. , Portnow Jana , D'Apuzzo Massimo , Forman Stephen J. , Jensen Michael C.
Published: April 2023

Supplementary Figure S4. 18F-Fluorodeoxyglucose ( F-FDG)-CT/PET of subjects UPN031 and UPN033
Supplemental Figure 3 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
Authors: Karjalainen Katja , Jaalouk Diana E. , Bueso-Ramos Carlos , Bover Laura , Sun Yan , Kuniyasu Akihiko , Driessen Wouter H.P. , Cardó-Vila Marina , Rietz Cecilia , Zurita Amado J. , O'Brien Susan , Kantarjian Hagop M. , Cortes Jorge E. , Calin George A. , Koivunen Erkki , Arap Wadih , Pasqualini Renata
Published: April 2023

Supplemental Figure 3. Drug activity of BMTP-11 and BMTP#4 on a panel of established leukemia and lymphoma cell lines.
Video 3 from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Authors: Lehmann Steffi , Perera Ramanil , Grimm Hans-Peter , Sam Johannes , Colombetti Sara , Fauti Tanja , Fahrni Linda , Schaller Teilo , Freimoser-Grundschober Anne , Zielonka Jörg , Stoma Szymon , Rudin Markus , Klein Christian , Umana Pablo , Gerdes Christian , Bacac Marina
Published: April 2023

Ex vivo analysis of the CEA TCB (magenta) mediated cross-linking of CFSE labeled T-cells (green) to tumor cells. 3D reconstructions of confocal z-stacks acquired on tumor sections obtained from huPBMC (CFSE labeled T-cells)/LS174T RFP co-grafts, 24 h after intravenous A647 labeled CEA TCB injections are shown. Bar, 10 ÃŽÂ¼m. Cell nuclei (DAPI) are shown in blue.
Suppl. Fig. Legends and Suppl. Methods from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Authors: Tateishi Kensuke , Iafrate A. John , Ho Quan , Curry William T. , Batchelor Tracy T. , Flaherty Keith T. , Onozato Maristela L. , Lelic Nina , Sundaram Sudhandra , Cahill Daniel P. , Chi Andrew S. , Wakimoto Hiroaki
Published: April 2023

Supplementary Figure Legends and Supplementary Methods
Supplemental Figure 1 from T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Authors: Kong Yaxian , Zhu Liuluan , Schell Todd D. , Zhang Jianhong , Claxton David F. , Ehmann W. Christopher , Rybka Witold B. , George Melissa R. , Zeng Hui , Zheng Hong
Published: April 2023

TIGIT expression associates with up-regulation of multiple inhibitory receptors.
Supplementary Figure 1 from Gain of HIF-1α under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes
Authors: Lee Young-Ho , Bae Hyun Cheol , Noh Kyung Hee , Song Kwon-Ho , Ye Sang-kyu , Mao Chih-Ping , Lee Kyung-Mi , Wu T.-C. , Kim Tae Woo
Published: April 2023

Supplementary Figure 1. VEGFA mRNA is up-regulated in human cancer cells subjected to immune selection.
Supplementary Table S1 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Authors: Klintman Marie , Buus Richard , Cheang Maggie Chon U. , Sheri Amna , Smith Ian E. , Dowsett Mitch
Published: April 2023

List of the selected genes, the associated biological process, prognostic and/or treatment predictive value in previous studies, and biological function. Apart from the 22 gene in the list below, the clinically established prognostic and treatment predictive genes ESR1 and ERBB2 were included.
Supplementary Figure S4 from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Authors: Klintman Marie , Buus Richard , Cheang Maggie Chon U. , Sheri Amna , Smith Ian E. , Dowsett Mitch
Published: April 2023

Association between CD3D mRNA expression values and IHC assessment of CD3D in residual disease
Supplementary Figure S6 from Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Authors: Karikoski Marika , Marttila-Ichihara Fumiko , Elima Kati , Rantakari Pia , Hollmén Maija , Kelkka Tiina , Gerke Heidi , Huovinen Ville , Irjala Heikki , Holmdahl Rikard , Salmi Marko , Jalkanen Sirpa
Published: April 2023

Supplementary Figure S6. Anti-Clever-1 treatment does not modify the severity of arthritis.
Supplementary Figure S3. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Authors: Chen Eddy J. , Sowalsky Adam G. , Gao Shuai , Cai Changmeng , Voznesensky Olga , Schaefer Rachel , Loda Massimo , True Lawrence D. , Ye Huihui , Troncoso Patricia , Lis Rosina L. , Kantoff Philip W. , Montgomery Robert B. , Nelson Peter S. , Bubley Glenn J. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Supplementary Figure S3. Dutasteride directly represses DHT and progesterone stimulated AR activity.
Table S1 from FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
Authors: Göke Friederike , Franzen Alina , Hinz Trista K. , Marek Lindsay A. , Yoon Petros , Sharma Rakesh , Bode Maike , von Maessenhausen Anne , Lankat-Buttgereit Brigitte , Göke Antonia , Golletz Carsten , Kirsten Robert , Boehm Diana , Vogel Wenzel , Kleczko Emily K. , Eagles Justin R. , Hirsch Fred R. , Van Bremen Tobias , Bootz Friedrich , Schroeck Andreas , Kim Jihye , Tan Aik-Choon , Jimeno Antonio , Heasley Lynn E. , Perner Sven
Published: April 2023

Table S1. The panel of HNSCC PDXs was submitted to FGFR1 gene copy number (GCN) by CISH and mRNA levels by in situ hybridization (ISH) assay.
Supplementary Figure S2. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Authors: Chen Eddy J. , Sowalsky Adam G. , Gao Shuai , Cai Changmeng , Voznesensky Olga , Schaefer Rachel , Loda Massimo , True Lawrence D. , Ye Huihui , Troncoso Patricia , Lis Rosina L. , Kantoff Philip W. , Montgomery Robert B. , Nelson Peter S. , Bubley Glenn J. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Supplementary Figure S2. Read depth and SNP ratio for PTEN and CHD1.
Supplementary Table S2 from Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Authors: Bonito Nair A. , Borley Jane , Wilhelm-Benartzi Charlotte S. , Ghaem-Maghami Sadaf , Brown Robert
Published: April 2023

Characteristics of the cell lines used in this study
Supplementary Figure S4 from Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Authors: Bonito Nair A. , Borley Jane , Wilhelm-Benartzi Charlotte S. , Ghaem-Maghami Sadaf , Brown Robert
Published: April 2023

FACS analysis using PI and BrdU following cisplatin treatment
Supplementary Figure S3 from Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Authors: Bonito Nair A. , Borley Jane , Wilhelm-Benartzi Charlotte S. , Ghaem-Maghami Sadaf , Brown Robert
Published: April 2023

Individual CpG site DNA methylation (beta values) grouped by PFS
Figure S3 from SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Authors: Piccione Emily C. , Juarez Silvia , Tseng Serena , Liu Jie , Stafford Melissa , Narayanan Cyndhavi , Wang Lijuan , Weiskopf Kipp , Majeti Ravindra
Published: April 2023

Supplementary Figure S3: SIRPabodies selectively bind to dual antigen-expressing cells in the presence of an antigen sink
SUPPLEMENTARY DATA from PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Authors: Sabbatino Francesco , Villani Vincenzo , Yearley Jennifer H. , Deshpande Vikram , Cai Lei , Konstantinidis Ioannis T. , Moon Christina , Nota Sjoerd , Wang Yangyang , Al-Sukaini Ahmad , Zhu Andrew X. , Goyal Lipika , Ting David T. , Bardeesy Nabeel , Hong Theodore S. , Fernandez-del Castillo Carlos , Tanabe Kenneth K. , Lillemoe Keith D. , Ferrone Soldano , Ferrone Cristina R.
Published: April 2023

SUPPLEMENTARY Table 1 Clinical relevance of the immunophenotypic staining of the ICC tumors
Supplementary Materials and Methods from Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6
Authors: Sun Hongcheng , Tang Huamei , Xie Dacheng , Jia Zhiliang , Ma Zhenyu , Wei Daoyan , Mishra Lopa , Gao Yong , Zheng Shaojiang , Xie Keping , Peng Zhihai
Published: April 2023

Immunohistochemistry and TMA Analysis Western Blot Analysis Cell Lines and Culture Conditions Plasmids and Small Interfering RNAs Transient Transfection Conditional Deletion of Klf4 in Murine Hepatocytes RNA Extraction, RT-PCR and Real-time PCR LCM Genotyping and Gene Expression Analyses Cell Immunofluorescence Construction of Mutant KLF4 ZFD-Expressing Vectors Construction of HNF-6 Promoter Reporter Plasmids and Mutagenesis Promoter Reporter and Dual Luciferase Assay ChIP Assay Cell Proliferation Assay Flow Cytometric Cell-Cycle Analysis Scratch Assay Cell Invasion Assay Mouse Xenograft Tumor Study
Supplementary Figure 3 from Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Authors: Lee Jiyoon , Condello Salvatore , Yakubov Bakhtiyor , Emerson Robert , Caperell-Grant Andrea , Hitomi Kiyotaka , Xie Jingwu , Matei Daniela
Published: April 2023

Supplementary Figure 3. Effect of TG2 knockdown on PDA cell proliferation and colony formation.
Supplementary Figure 2. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

OTX015 effect on cell viability positively correlates with MYCN status. (a) IC50 of the IMR 5, Chp 134, Chp 212, SK N-BE(2), IMR-32, SK-N-BE, NB69, SK N AS and GI-M-EN neuroblastoma cell lines measured using MTT assays. (b) Maximum reduction of viability in IMR 5, Chp 134, Chp 212, SK N-BE(2), IMR-32, SK-N-BE, NB69, SK N AS and GI-M-EN cells treated for 72 h with 6 µM OTX015 and measured using MTT assays. (c) Relative MYCN mRNA (top) and protein (bottom) expression in all analyzed neuroblastoma cell lines. (d/e) The IC50 values of the cell lines shown in (a) were plotted against MYCN mRNA expression (d) or MYCN protein expression (e), which is shown in (c). Both graphs show weak anti-correlative tendencies in both cell lines (MYCN mRNA p=0.22, MYCN protein p=0.16).
Supplemental Tables 1-3 from IgG Glycome in Colorectal Cancer
Authors: Vučković Frano , Theodoratou Evropi , Thaçi Kujtim , Timofeeva Maria , Vojta Aleksandar , Štambuk Jerko , Pučić-Baković Maja , Rudd Pauline M. , Đerek Lovorka , Servis Dražen , Wennerström Annika , Farrington Susan M. , Perola Markus , Aulchenko Yurii , Dunlop Malcolm G. , Campbell Harry , Lauc Gordan
Published: April 2023

Supplementary Table 1. Directly measured glycans and derived glycan traits; Supplementary Table 2. IgG glycome composition in CRC patients and controls; Supplementary Table 3. Pleiotropic effects of top glycan SNPs relevant for fucosylation on CRC.
Data File S1 from A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer
Authors: Hoogstins Charlotte E.S. , Tummers Quirijn R.J.G. , Gaarenstroom Katja N. , de Kroon Cor D. , Trimbos J. Baptist M.Z. , Bosse Tjalling , Smit Vincent T.H.B.M. , Vuyk Jaap , van de Velde Cornelis J.H. , Cohen Adam F. , Low Philip S. , Burggraaf Jacobus , Vahrmeijer Alexander L.
Published: April 2023

Exploratory evaluation of potential hypersensitivity responses to compound OTL38 utilizing human, in vitro, highly sensitive models